|

Paclitaxel Clinical Trials

209 actively recruiting trials across 56 locations

▼ -4 trials since May 2026

Also known as: 33069-62-4,5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one,4,10-Diacetate 2-Benzoate 13-Ester with (2R,3S)-N-Benzoyl-3-phenylisoserine, [2aR-[2a Alpha,4beta,4a beta,6beta, 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine, ABRAXANE®, Abraxane, Abraxane, Taxol +33 more

Pipeline

Early 1: 3Phase 1: 26Phase 2: 84Phase 3: 57Phase 4: 2Phase 1/2: 26Phase 2/3: 6

Top Sponsors

  • Merck Sharp & Dohme LLC18
  • National Cancer Institute (NCI)15
  • M.D. Anderson Cancer Center8
  • AstraZeneca8
  • University of Chicago4

Indications

Other72 trials

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
Phase 1
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Phase 1/2
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
Phase 3
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
Phase 3
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Phase 2
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Phase 2
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3
A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Phase 1
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Phase 3
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Phase 1/2
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Phase 2
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 3
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Phase 3
A Study of TXN10128 in Subjects With Solid Tumors
Phase 1
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
Phase 1
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Phase 2
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Phase 1/2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Phase 2
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Phase 1/2
AK129 Combination Therapy for Advanced Solid Tumors
Phase 1/2
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
Phase 2
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Phase 3
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Phase 2
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Phase 2/3
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
Phase 2
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Phase 1
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Phase 2
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Phase 3
Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread
Phase 3
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
Phase 1/2
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC
Phase 2
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Phase 2
MicroRNA Profiles in Triple Negative Breast Cancer
Phase 2
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
Phase 2
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
Phase 2
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
Phase 2
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
Phase 2
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Phase 3
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Phase 2
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
Phase 2
PALACE: Cemiplimab Trial According to ctDNA Levels
Phase 2
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Phase 3
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Phase 2
Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
Phase 2
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
Phase 3
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Phase 1/2
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis
Phase 1
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Phase 2
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Phase 3
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Phase 2
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Phase 3
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
Phase 2
Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Phase 1/2
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Phase 3
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
Phase 2
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Phase 3
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
Phase 3
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
N/A
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Phase 3
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Phase 3
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
Phase 2
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 3
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Phase 2
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
Phase 2
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Phase 3

Birmingham, Alabama10 trials

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

University of Alabama at Birmingham

Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

University of Alabama at Birmingham

Phase 2
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

University of Alabama at Birmingham Cancer Center

Phase 2
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

University of Alabama at Birmingham Cancer Center

Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Houston, Texas10 trials

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

MD Anderson Cancer Center

Phase 1/2
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

M D Anderson Cancer Center

Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Harris Health System - Smith Clinic

Phase 2
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

MD Anderson Cancer Centre

N/A
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M D Anderson Cancer Center

Phase 1
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

M D Anderson Cancer Center

Phase 2
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

M D Anderson Cancer Center

Phase 1
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

MD Anderson Cancer Center

Phase 2
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

M D Anderson Cancer Center

Phase 1
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

M D Anderson Cancer Center

Phase 1

Tucson, Arizona8 trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site

Phase 3
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)

Phase 1/2
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

The University of Arizona Cancer Center - North Campus

Phase 2
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Research Site

Phase 3
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Research Site

Phase 3
Study of Novel Treatment Combinations in Patients With Lung Cancer

Arizona Oncology Associates,Substudy-01

Phase 2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927)

Phase 1/2
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Banner University Medical Center - Tucson

Phase 2

Duarte, California8 trials

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

City of Hope

Phase 3
A Study of NX-1607 in Adults With Advanced Malignancies

City of Hope

Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

City of Hope

Phase 2
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases

City of Hope Medical Center

Phase 1
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

City of Hope

Phase 1
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2
Study of INCB123667 in Subjects With Advanced Solid Tumors

City of Hope Medical Center

Phase 1

Phoenix, Arizona6 trials

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site

Phase 1/2
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Cancer Center at Saint Joseph's

Phase 3
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

HonorHealth

Phase 3
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Mayo Clinic Hospital in Arizona

Phase 3
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Mayo Clinic

Phase 3
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Mayo Clinic Hospital in Arizona

Phase 1

Chicago, Illinois6 trials

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

University of Chicago Comprehensive Cancer Center

Phase 2
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

University of Illinois

Phase 2
LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

University of Illinois Cancer Center

N/A
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

University of Chicago Medicine Comprehensive Cancer Center

Phase 1
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

The University of Chicago

Phase 2
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

The University of Chicago Medicine Comprehensive Cancer Center

Phase 2

Anchorage, Alaska5 trials

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Alaska Women's Cancer Care

Phase 2/3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Alaska Oncology and Hematology

Phase 2/3
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Anchorage Associates in Radiation Medicine

Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Alaska Oncology and Hematology, LLC

Phase 2/3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Anchorage Associates in Radiation Medicine

Phase 3

Los Angeles, California5 trials

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1/2
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Los Angeles County-USC Medical Center

Phase 3
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Research Site

Phase 2
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Los Angeles General Medical Center

Phase 1/2
Volrustomig Priming Regimens Exploratory Phase II Platform Study

Research Site

Phase 2

Daphne, Alabama3 trials

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Southern Cancer Center (SCC) ( Site 8000)

Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Research Site

Phase 3
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Southern Cancer Center (SCC) ( Site 8004)

Phase 2

Gilbert, Arizona3 trials

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Banner MD Anderson Cancer Center ( Site 0066)

Phase 3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Banner MD Anderson Cancer Center ( Site 0181)

Phase 3
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Banner MD Anderson Cancer Center ( Site 0001)

Phase 1/2

Little Rock, Arkansas3 trials

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060)

Phase 3
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Baptist Health Medical Center - Little Rock

Phase 2/3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

CARTI Cancer Center ( Site 0006)

Phase 3

La Jolla, California3 trials

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

University of California at San Diego Moores Cancer Center

Phase 1/2
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

University of Southern California

Phase 1
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

UC San Diego Moores Cancer Center

Phase 2

Tampa, Florida3 trials

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Moffitt Cancer Center ( Site 0021)

Phase 2
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Moffitt Cancer Center

Phase 2
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Moffitt Cancer Center

Phase 2

Lexington, Kentucky3 trials

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

University of Kentucky ( Site 0019)

Phase 2
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

University of Kentucky Chandler Medical Center

Phase 1
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

University of Kentucky/Markey Cancer Center

Phase 2

Boston, Massachusetts3 trials

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Beth Israel Deaconess Medical Center (BIDMC)

Phase 1
Folfox+Irinotecan+Chemort In Esophageal Cancer

Massachusetts General Hospital

Phase 2
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2

Columbus, Ohio3 trials

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Ohio State University Comprehensive Cancer Center

Phase 2
Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 2
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Ohio State University Comprehensive Cancer Center

Early 1

Mobile, Alabama2 trials

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

USA Mitchell Cancer Institute ( Site 0090)

Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

University of South Alabama, Mitchell Cancer Institute ( Site 6033)

Phase 3

Fullerton, California2 trials

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Providence Medical Foundation

Phase 3
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Providence Medical Foundation -Fullerton

Phase 2

San Francisco, California2 trials

ATEMPT 2.0: Adjuvant T-DM1 vs TH

UCSF Helen Diller Family Comprehensive Cancer Center

Phase 2
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

University of California, San Francisco

Phase 1

Santa Monica, California2 trials

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

UCLA

Phase 1
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

UCLA Hematology/Oncology - Parkside ( Site 0021)

Phase 2

Aurora, Colorado2 trials

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Site 0264

Phase 1
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

University of Colorado Cancer Center

Phase 1

Washington D.C., District of Columbia2 trials

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

MedStar Washington Hospital Center

Phase 3
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

Lombardi Comprehensive Cancer Center, Georgetown University

Phase 2

Atlanta, Georgia2 trials

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

Emory University Hospital Midtown

Phase 2
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Emory University Hospital/Winship Cancer Institute

Phase 2

Baltimore, Maryland2 trials

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Johns Hopkins Medicine SKCCC

Phase 1/2

Bethesda, Maryland2 trials

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute Developmental Therapeutics Clinic

Phase 2
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center

Phase 1/2

Ann Arbor, Michigan2 trials

Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial

University of Michigan Comprehensive Cancer Center

Phase 2
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

University of Michigan Rogel Cancer Center

Phase 4

Rochester, Minnesota2 trials

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Mayo Clinic- Minnesota

Phase 2
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Mayo Clinic in Rochester

Phase 2

Basking Ridge, New Jersey2 trials

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

Memorial Sloan Kettering Basking Ridge (All protocol activities)

Early 1

Philadelphia, Pennsylvania2 trials

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Abramson Cancer Center of the University of Pennsylvania

Phase 2
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2

Pittsburgh, Pennsylvania2 trials

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

UPMC Hillman Cancer Center

Phase 2
Window of Opportunity in Preserving Laryngeal Function Trial

UPMC Hillman Cancer

Phase 2

Seattle, Washington2 trials

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Chandler, Arizona1 trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Ironwood Cancer & Research Centers ( Site 0066)

Phase 3

Scottsdale, Arizona1 trial

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Mayo Clinic in Arizona

Phase 1/2

Fayetteville, Arkansas1 trial

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Highlands Oncology Group - Fayetteville

Phase 3

Hot Springs, Arkansas1 trial

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Local Institution - 0303

Phase 2/3

Beverly Hills, California1 trial

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Precision NextGen Oncology

Phase 1/2

Long Beach, California1 trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Oncology Institute

Phase 2

Orange, California1 trial

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

University of California Irvine Medical Center

Phase 1

San Diego, California1 trial

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

University of California San Diego

Phase 1/2

Stanford, California1 trial

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Stanford University

Phase 3

Fort Lauderdale, Florida1 trial

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Research Site

Phase 3

Jacksonville, Florida1 trial

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Mayo Clinic Jacksonville

Phase 1

Miami Beach, Florida1 trial

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Mount Sinai Comprehensive Cancer Center ( Site 6000)

Phase 3

Orlando, Florida1 trial

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Advent Health

Phase 3

Maywood, Illinois1 trial

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Loyola University Medical Center

Phase 2

Indianapolis, Indiana1 trial

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Phase 2

Iowa City, Iowa1 trial

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

University of Iowa Health Care/Holden Comprehensive Cancer Center

Phase 4

Louisville, Kentucky1 trial

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

The University of Louisville, James Graham Brown Cancer Center ( Site 0009)

Phase 1/2

Detroit, Michigan1 trial

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2

Traverse City, Michigan1 trial

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Munson Medical Center ( Site 0812)

Phase 3

Elizabeth, New Jersey1 trial

ATATcH Alternating Treatment Plans for Advanced Cancer

Trinitas Hospital and Comprehensive Cancer Center

Phase 2

New York, New York1 trial

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Mount Sinai Health System

Early 1

Winston-Salem, North Carolina1 trial

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Wake Forest Baptist Comprehensive Cancer Center

Phase 2

Portland, Oregon1 trial

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

OHSU Knight Cancer Institute

Phase 1/2

Charleston, South Carolina1 trial

NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

Medical University of South Carolina

Phase 2

Nashville, Tennessee1 trial

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Vanderbilt University/Ingram Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.